Compositions of myeloid-cell-suppressive chemokines
US6143289A · kind A · utility
1Cited by
3References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 9, 1992 |
| Grant date | Nov 7, 2000 |
| Priority date | — |
| Expiry date | Dec 9, 2012 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/23
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described are preferred processes for suppressing proliferation of or for myeloprotecting myeloid cells in mammals. The processes involve the use of chemokines of the group Macrophage Inflammatory Protein-2.alpha. (MIP-2.alpha.), Platelet Factor 4 (PF4), Interleukin-8 (IL-8) and Macrophage Chemotactic and Activating Factor (MCAF), or involve the use of these chemokines or Macrophage Inflammatory Protein-1.alpha. (MIP-1.alpha.) in synergistic combinations or while they are substantially completely in monomeric form (i.e. substantially free from their polymerized or aggregated forms).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.